S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Laser breakthrough could send stock soaring 2,467% (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Laser breakthrough could send stock soaring 2,467% (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Laser breakthrough could send stock soaring 2,467% (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Laser breakthrough could send stock soaring 2,467% (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price & News

$18.31
-0.19 (-1.03%)
(As of 09/29/2023 ET)
Compare
Today's Range
$18.15
$18.90
50-Day Range
$18.08
$23.45
52-Week Range
$17.80
$41.93
Volume
822,236 shs
Average Volume
1.03 million shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.40

Amylyx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
169.8% Upside
$49.40 Price Target
Short Interest
Bearish
19.10% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.65mentions of Amylyx Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
164.66%
From $1.16 to $3.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

157th out of 971 stocks

Pharmaceutical Preparations Industry

50th out of 443 stocks


AMLX stock logo

About Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Price History

AMLX Stock News Headlines

25 Biggest Stocks with Negative Beta
14 Best Depressed Stocks To Buy Now
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Amylyx Pharmaceuticals: A High Risk/High Reward Stock
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
AMLX - Amylyx Pharmaceuticals, Inc.
Q2 2023 Amylyx Pharmaceuticals Inc Earnings Call
Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from Mizuho Securities
Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs
Why Shares of Amylyx Pharmaceuticals Were Up Monday
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMLX
Fax
N/A
Employees
338
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.40
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+169.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-198,380,000.00
Pretax Margin
-36.79%

Debt

Sales & Book Value

Annual Sales
$191.87 million
Book Value
$5.14 per share

Miscellaneous

Free Float
59,427,000
Market Cap
$1.23 billion
Optionable
Not Optionable
Beta
-0.93
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Joshua B. Cohen (Age 31)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. Justin B. Klee (Age 32)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. James M. Frates M.B.A. (Age 56)
    Chief Financial Officer
    Comp: $695.12k
  • Ms. Gina M. Mazzariello (Age 52)
    Chief Legal Officer & Gen. Counsel
    Comp: $794.83k
  • Mr. Tom Holmes
    Chief Technical Operations Officer
  • Lindsey Allen
    Head of Investor Relations & Communications
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Debra L. Canner (Age 64)
    Global Head of HR & CHRO
  • Ms. Margaret M. Olinger M.B.A (Age 58)
    Global Head of Commercial & Chief Commercial Officer
  • Dr. Patrick D. Yeramian M.D. (Age 64)
    MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer













AMLX Stock - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings
or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued 1 year price objectives for Amylyx Pharmaceuticals' stock. Their AMLX share price forecasts range from $48.00 to $50.00. On average, they predict the company's share price to reach $49.40 in the next year. This suggests a possible upside of 169.8% from the stock's current price.
View analysts price targets for AMLX
or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2023?

Amylyx Pharmaceuticals' stock was trading at $36.95 at the start of the year. Since then, AMLX stock has decreased by 50.4% and is now trading at $18.31.
View the best growth stocks for 2023 here
.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our AMLX earnings forecast
.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its earnings results on Thursday, August, 10th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.30. The company had revenue of $98.22 million for the quarter, compared to analysts' expectations of $84.30 million. Amylyx Pharmaceuticals had a negative net margin of 37.95% and a negative trailing twelve-month return on equity of 23.80%.

Is Amylyx Pharmaceuticals a good dividend stock?

Amylyx Pharmaceuticals (NASDAQ:AMLX) pays an annual dividend of $1.02 per share and currently has a dividend yield of 0.00%.

When did Amylyx Pharmaceuticals IPO?

(AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.

What is Amylyx Pharmaceuticals' stock symbol?

Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX."

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amylyx Pharmaceuticals' stock price today?

One share of AMLX stock can currently be purchased for approximately $18.31.

How much money does Amylyx Pharmaceuticals make?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.23 billion and generates $191.87 million in revenue each year. The company earns $-198,380,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How many employees does Amylyx Pharmaceuticals have?

The company employs 338 workers across the globe.

How can I contact Amylyx Pharmaceuticals?

The official website for the company is amylyx.com. The company can be reached via phone at 617-682-0917 or via email at investors@amylyx.com.

This page (NASDAQ:AMLX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -